Loading company…
Seoul-based developer of exosome-based therapies, led by its SNE-101 candidate for acute ischemic stroke.
Founded in 2019 in Seoul, South Korea, S&E bio Co., Ltd. develops exosome-based cell therapies for intractable diseases. Its lead product, SNE-101, targets acute ischemic stroke by promoting neurovascular regeneration and reducing oxidative stress and inflammation. The company works with hospitals on clinical trials and plans to expand across Asia. In December 2022 it raised KRW 9.3 billion in Series A funding from Infobank, Samsung Life Public Welfare Foundation, LSK Investment, JW Pharmaceutical, Korea Investment Partners, KB Investment and Company K Partners. CEO is Oh-young Bang.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in